Results 231 to 240 of about 103,385 (306)

Medical haematology: Repositioning haematology at the centre of medicine

British Journal of Haematology, EarlyView.
The complementary domains of Medical Haematology and Haemato‐Oncology share a biological framework. The left panel depicts red cells, platelets, coagulation, thrombosis and innate immunity, while the right panel shows lymphoid and myeloid malignancies.
Cheng Hock Toh, Imelda Bates, Sue Pavord
wiley   +1 more source

ALK‐negative anaplastic large‐cell lymphoma demonstrates similar poor prognosis to peripheral T‐cell lymphoma, unspecified

, 2003
Rosita L. ten Berge, Peter C. de Bruin, Joost J. Oudejans, G.J. Ossenkoppele, Paul van der Valk, Chris J.L.M. Meijer   +5 more
openalex   +2 more sources

Protein tyrosine phosphatases as emerging targets for cancer immunotherapy

British Journal of Pharmacology, EarlyView.
Abstract Contemporary strategies in cancer immunotherapy, despite remarkable success, remain constrained by inherent limitations such as suboptimal patient responses, the emergence of drug resistance, and the manifestation of pronounced adverse effects. Consequently, the need for alternative strategies for immunotherapy becomes clear.
Zihan Qu, Jiajun Dong, Zhong‐Yin Zhang
wiley   +1 more source

Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study [PDF]

, 2018
et al,, Gambacorti-Passerini, Carlo, Van Tine, Brian A   +2 more
core   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Detection of residual host cells after bone marrow transplantation using non-isotopic in situ hybridization [PDF]

, 1993
Cremer, Thomas, Knuutila, Sakari, Popp, Susanne, Ruutu, Tapani, Volin, L., Wessman, M.   +5 more
core  

Supplementary Data1 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma

Julio C. Chávez, Francine M. Foss, Basem M. William, Jonathan E. Brammer, Sonali M. Smith, Anca Prica, Jasmine M. Zain, Joseph M. Tuscano, Harsh Shah, Neha Mehta–Shah, Praveen Ramakrishnan Geethakumari, Ben X. Wang, Stephanie Zantinge, Lisa Wang, Ling Zhang, Anmarie Boutrin, Weiguang Zhao, Lily Cheng, Nathan Standifer, Lisa Hewitt, Enowmpey Enowtambong, Weiping Shao, Shringi Sharma, Gianluca Carlesso, Jeffrey A. Moscow, Lillian L. Siu   +25 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

British Journal of Pharmacology, EarlyView.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang, Sijia Zhu, Na Xing, Zhen Zhou, Jiayi Chen, Tianen Si, Mingrui Li, Lin Jia, Yousef Rastegar‐Kashkooli, Tom J. Wang, Wei Zhu, Jing Li, Chao Jiang, Junmin Wang, Moxin Wu, Xiaoping Yin, Weidong Zang, Jian Wang, Songxue Su   +18 more
wiley   +1 more source

Combinatorial targeting of MYC/BCL2‐associated vulnerabilities in high‐grade B‐cell lymphoma

British Journal of Haematology, EarlyView.
Giulio Donati, Paola Nicoli, Federica Miele, Paola Podini, Giorgia Dina, Angelo Quattrini, Bruno Amati   +6 more
wiley   +1 more source